CRA is exhibiting at the conference at booth #2018.
Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?” discussing:
Determining a price for a novel rare disease therapy with few benchmarks can be challenging. In this session we present insights from research on how payers and physicians perceive prices for curative and chronic rare disease therapies, and specifically, under what circumstances do they consider higher prices to be fair. We further explore how perceptions of pricing fairness may be used in understanding the value of a new rare disease treatment. Primary market research with payers and physicians was conducted both before and after the COVID pandemic, and provides insights to how perceptions of pricing fairness have changed.
For more information on this event, click here.
